Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.
“Winning this award is an exciting achievement for Nutra Pharma, as it reflects the significant amount of positive response we have received from retailers who are looking to offer their customers a safe and effective alternative to current pain relievers,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma. “As we begin introducing Cobroxin through retailers this fall, we plan to continue our efforts educating both retailers and consumers about Cobroxin’s unique analgesic properties, which do not rely on opiates or acetaminophen for its pain relieving effects,” he concluded.